Smoking remains the primary preventable cause of death in the United States and throughout the world. 70% of smokers want to quit, and 90% of those who try fail.
Assuage Pharmaceuticals is a pre-clinical stage biotechnology company dedicated to helping people stop smoking. As a spin-out from the Torrey Pines Institute for Molecular Studies, Assuage is developing innovative new first-in-class products that are more effective, and safer than currently available products. Our goal is to help reduce the number of people who smoke, and to help reduce the economic burden of smoking related diseases in the US and around the world.
Assuage Pharmaceuticals is developing novel new therapeutics to significantly reduce the craving for nicotine, and to reduce the chances of relapse (starting to smoke again).. The Assuage approach is both novel and unique. Our First-in-class high affinity antagonists have shown exquisite selectivity for the most important nicotine receptor, which we believe can lead to better effectiveness, and greatly reduced side effects.